Peptide Library

Human study PLS-00057

MOTS-c as a Potential Diagnostic-prognostic Biomarker for Myocardial Infarction.

Case-control study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • MOTS-c as a Potential Diagnostic-prognostic Biomarker for Myocardial Infarction.primary · Cardiovascular & hematological agents in medicinal chemistry · 2025-01-01 · PMID 40353474 · DOI

Design and participants

Design
Case-control study
Population
Patients undergoing coronary angiography: those with significant obstructive coronary lesions (myocardial infarction group) and those without obstructive lesions (control group).
Conditions
Myocardial infarction
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Serum MOTS-c correlated negatively with platelets and troponin I in MI patients, suggesting the peptide may help, alongside other parameters, in diagnostic and therapeutic evaluation of MI.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: Endogenous MOTS-c levels were measured as a biomarker. The compound was not given, so no effect of MOTS-c administration can be inferred.
    • abstract only: Only the abstract is available. Sample sizes, methods and full results are not reported in the record.
    • confounding: Groups were defined by angiography findings, with no stated adjustment for confounders; correlations were exploratory.
    • small or imprecise: Group sizes are not stated, and the correlations are modest with p-values near 0.05, with no confidence intervals.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 40353474, abstract (Conclusion, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 40353474, abstract (Methods, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 40353474, abstract (Objectives and Methods sentences) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 40353474, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).